TY - JOUR T1 - Transnasal Aerosol Delivery During High-Flow Nasal Cannula Therapy JF - Respiratory Care SP - 149 LP - 150 DO - 10.4187/respcare.09814 VL - 67 IS - 1 AU - Jessica L Saunders AU - Michael D Davis Y1 - 2022/01/01 UR - http://rc.rcjournal.com/content/67/1/149.abstract N2 - Since the introduction of high-flow nasal cannula therapy (HFNC), interest has grown in the delivery of aerosolized medications through this interface.1 This is not surprising because many patients requiring HFNC also require inhaled medications such as bronchodilators or pulmonary vasodilators, and an interruption of their HFNC would be inconvenient and potentially dangerous. Moreover, conventional delivery of aerosolized medications by a mouthpiece or face mask involves oral inhalation, which can lower the effectiveness of HFNC. Although transnasal aerosol delivery through HFNC has become common practice at many centers throughout the world, high-quality data regarding the efficacy and most effective methods are lacking.2 In this issue of Respiratory Care, two primary research manuscripts are included related to these topics.In the manuscript written by Li et al, the authors conducted several in vitro experiments to evaluate the effects of different HFNC devices, circuits, nebulizers, and nebulizer locations on aerosolized medication delivery at different simulated breathing patterns and HFNC flow settings. They found that vibrating … Correspondence: Michael D Davis RRT PhD FAARC, 1044 W. Walnut Street R4-472, Indianapolis, Indiana 46202. E-mail: MDD1{at}iu.edu ER -